Ann Varanakis Sells 50,000 Shares of LifeStance Health Group (NASDAQ:LFST) Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) insider Ann Varanakis sold 50,000 shares of LifeStance Health Group stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $6.90, for a total value of $345,000.00. Following the sale, the insider directly owned 315,610 shares in the company, valued at $2,177,709. The trade was a 13.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

LifeStance Health Group Stock Performance

LifeStance Health Group stock opened at $7.05 on Friday. The business has a 50 day moving average of $5.99 and a 200-day moving average of $5.37. The company has a market capitalization of $2.74 billion, a P/E ratio of -235.00 and a beta of 1.13. LifeStance Health Group, Inc. has a 1 year low of $3.74 and a 1 year high of $8.30. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.58 and a quick ratio of 1.58.

LifeStance Health Group (NASDAQ:LFST) last posted its earnings results on Wednesday, November 5th. The company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. The firm had revenue of $363.81 million for the quarter, compared to analyst estimates of $355.06 million. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The company’s revenue for the quarter was up 16.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.02) EPS. On average, equities research analysts predict that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on LFST. Wall Street Zen downgraded shares of LifeStance Health Group from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. BTIG Research lifted their target price on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Barclays initiated coverage on shares of LifeStance Health Group in a report on Tuesday, December 9th. They issued an “overweight” rating and a $8.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of LifeStance Health Group in a report on Monday, December 15th. Finally, UBS Group lifted their price objective on LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.83.

Institutional Investors Weigh In On LifeStance Health Group

A number of large investors have recently bought and sold shares of the stock. Bayesian Capital Management LP bought a new stake in LifeStance Health Group in the second quarter valued at $52,000. Park Edge Advisors LLC acquired a new stake in shares of LifeStance Health Group in the 2nd quarter valued at about $52,000. Vanguard Personalized Indexing Management LLC bought a new stake in LifeStance Health Group in the 3rd quarter valued at about $72,000. Blair William & Co. IL bought a new stake in LifeStance Health Group in the 2nd quarter valued at about $70,000. Finally, Public Employees Retirement System of Ohio acquired a new position in LifeStance Health Group during the 2nd quarter worth approximately $70,000. 85.50% of the stock is currently owned by institutional investors and hedge funds.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.